Ross C, Tingsgaard P, Jørgensen H, Vejlsgaard G L
Dep. of Dermatology, University Hospital of Copenhagen, Denmark.
Eur J Haematol. 1993 Aug;51(2):63-72. doi: 10.1111/j.1600-0609.1993.tb01595.x.
In this report we have reviewed studies on the clinical effect of the interferon (IFN) treatment of 304 patients suffering from cutaneous T-cell lymphoma (CTCL). Intramuscular, subcutaneous or intralesional administration of recombinant IFN has been used as monotherapy or as part of combination therapy. In general, IFN has proved to be a relatively effective agent in the treatment of CTCL, and the best responses have been achieved in the early stages of the disease. In CTCL the overall response rate to IFN including complete, partial and minor responses is 70%. Neither the doses nor the routes of administration in these studies has any statistically significant influence on the clinical response to IFN treatment. Continuous low-dose IFN therapy, presumably in combination with psoralen and UVA light (PUVA), is recommended. This review concludes that the clinical stage of disease before treatment is the only known predictive parameter concerning the clinical response to IFN treatment in patients with CTCL.
在本报告中，我们回顾了关于干扰素（IFN）治疗304例皮肤T细胞淋巴瘤（CTCL）患者的临床疗效的研究。重组IFN的肌内、皮下或病灶内给药已被用作单一疗法或联合疗法的一部分。总体而言，IFN已被证明是治疗CTCL的一种相对有效的药物，并且在疾病的早期阶段取得了最佳疗效。在CTCL中，对IFN的总体反应率（包括完全缓解、部分缓解和轻微缓解）为70%。这些研究中的剂量和给药途径对IFN治疗的临床反应均无统计学上的显著影响。推荐持续低剂量IFN治疗，可能与补骨脂素和紫外线A光（PUVA）联合使用。本综述得出结论，治疗前疾病的临床分期是CTCL患者对IFN治疗临床反应的唯一已知预测参数。
